DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-449/S-003

Gilead Sciences, Inc
ATTN: Martine Kraus, PhD
Director, Regulatory Affairs
333 Lakeside Drive
Foster City, CA 94404

Dear Dr. Kraus:

Please refer to your supplemental new drug application dated October 21, 2003 and received October 23, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for HEPSERA (adefovir dipivoxil, ADV) 10 mg Tablets.

We acknowledge receipt of your submissions dated:

March 17, 2004	June 14, 2004	August 13, 2004
March 18, 2004	June 21, 2004	August 16, 2004 (2)
March 23, 2004	July 26, 2004	August 17, 2004
April 16, 2004	August 6, 2004	August 18 2004
May 7, 2004	August 10, 2004	

This supplemental new drug application provides for inclusion of safety and efficacy data from study GS-98-438 through 96 weeks and from study GS-00-461 through 48 weeks to the HEPSERA package insert.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert (PI) and text for the patient package insert (PPI) submitted August 18, 2004. The final printed labeling (FPL) must be formatted in accordance with the requirements of 21 CFR 201.66. These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry entitled *Providing Regulatory Submissions in Electronic Format – NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "**FPL for approved supplement NDA 21-449/S-003**." Approval of this submission by FDA is not required before the labeling is used.

We also remind you of the agreed-upon postmarketing commitments in your NDA approval letter dated September 20, 2002.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Protocol**", "**Postmarketing Study Final Report**", or "**Postmarketing Study Correspondence**."

If you issue a letter communicating important information about this drug product (*i.e.*, a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Marsha Holloman, Regulatory Health Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra B. Birnkrant, MD
Division Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure: Package Insert and Patient Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Debra Birnkrant
8/19/04 04:19:05 PM
NDA 21-449